InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc

Bullboard Posts

Comment by Moneymagnet14on Feb 25, 2015 4:52pm

55 Views

Post# 23465324

RE:RE:RE:RE:RE:Still undervalued

Agreed, i'm not making a comparison but GWPH had well over 90 million shares outstanding and now has nearly 300 million out as it stands...GWPH is trading around $85 a share right now. Obviously InMed is a hell of a long way off but it is truly unique in a niche market. Already has 1 of the top scientists in the country at the helm, give this company 6 months..who know it may end up surpassing everyones expectations.

Bullboard Posts

Changing Europe’s dependency on HREE from China